TrialInternational journal of hematology2018

Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.

Keita Kirito et al.PubMed ↗Publisher ↗

No numbers read from the abstract.